Gamma Vaccines acquires IP to develop NDV vaccine

Gamma Vaccines has signed a deed of assignment with the University of Adelaide for the rights to commercialise vaccines for NDV (Newcastle disease), either alone or in combination with our other proprietary vaccines.

Share this post

12/09/2024
Gamma vaccines signs international collaboration agreement.
Gamma vaccines has entered a collaboration agreement with Capricorn Technologies GmBH (Austria) and Aptum Adjuvants Ltd (UK) to…

Read article
05/09/2024
Gamma Vaccines files patent on combination vaccines
Gamma Vaccines has filed a patent application on combination vaccines that incorporate our photon-inactivated vaccine with other immunogens,…

Read article
27/05/2024
Gamma Vaccines receives R&D tax credit.
Gamma vaccines receives an R&D Tax Credit for R&D conducted in FY2023 for the amount of $28,538.84.

Read article

View All Articles

Gamma Vaccines acquires IP to develop NDV vaccine

Share this post

Related Articles

Gamma vaccines signs international collaboration agreement.

Gamma Vaccines files patent on combination vaccines

Gamma Vaccines receives R&D tax credit.